Idenix (IDIX) announces removal of partial clinical hold on HCV nucleotide inhibitor, IDX184
Tweet
Share
E-mailGet Alerts IDIX Hot Sheet
Join SI Premium – FREE
Idenix (Nasdaq: IDIX) announces removal of partial clinical hold on HCV nucleotide inhibitor, IDX184
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Caris Life Sciences publishes AI therapy study for pancreatic cancer
- Dolby names Marc Whitten CEO as Kevin Yeaman retires
- Mistras Group names AI executive director in strategy push
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
